Company ProfilePremium

Acrux Limited

Company Profile Analysis

Ticker: ACR.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Acrux Limited - Company showcase

Year Founded & Workforce

1998

23 Employees

Acrux Limited logo

Acrux Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Acrux Limited Overview

Acrux Limited is a Melbourne-based micro-capitalisation specialty pharmaceutical company with a 25-year heritage in transdermal and topical drug delivery, best known for inventing the "patchless patch" metered-dose transdermal spray technology behind Evamist/Lenzetto (estradiol) and Axiron (male testosterone), the latter licensed to Eli Lilly in 2010 in a deal valued at up to US$335 million. After Axiron's commercial collapse in 2017, Acrux spent 2017–2025 building a portfolio of US generic topical products under ANDAs, achieving multiple FDA approvals but only modest licensing income. In FY2026, under new CEO John Warmbrunn, the company ceased its generic pipeline, monetised legacy assets and repositioned around a single high-value asset: a Female Testosterone Metered Dose Transdermal System for Hypoactive Sexual Desire Disorder (HSDD), a market without an FDA-approved testosterone product for women. Acrux now seeks a co-development partner to fund Phase III, while living off a small profit-share and milestone income base.


Company's own description. In its FY2026 Annual Report, Acrux describes itself as a specialty pharma company with a successful track record of developing and commercialising topically applied pharmaceutical products, drawing on 25 years of experience and having marketed products through licensees worldwide with emphasis on the United States. Crucially, the FY2026 Appendix 4E and Directors' Report add that during FY26 there was "a shift of emphasis to the development of testosterone to be applied transdermally in a metered dose suitable for women and cessation of progression of the topical generic pipeline." The Annual Report's cover theme is "Female Testosterone MDTS — the catalyst to accelerate Acrux's commercial success," and management states that Acrux will pursue Female Testosterone "through licensing its intellectual property using a co-development business model."

What the company does. Acrux formulates, develops and obtains regulatory approval for topically and transdermally applied medicines, and then out-licenses commercialisation to in-market partners. It does not manufacture at commercial scale (it uses contract manufacturing organisations; eight CMOs were contracted as at FY24) and it does not operate its own sales force. Its West Melbourne site (1,735 m²) houses laboratories, offices and warehousing, and is licensed by the TGA to manufacture certain products to clinical-trial stage.

Business model and revenue model. Acrux is a licensing and royalty business. Its revenue model has four strands, all disclosed in FY2026 Note 4: (1) profit share and royalty income from US generic products marketed by licensees (TruPharma, Padagis) — AUD 2,948k in FY26, including AUD 829k (US$550k) from the divestment of the Prilocaine/Lidocaine cream ANDA; (2) licensing and milestone income — AUD 1,350k in FY26 from Gedeon Richter's Australian Lenzetto licence, with up to a further AUD 4,050k contingent on TGA approval and sales; (3) fee-for-service technical work for third parties — AUD 346k in FY26; and (4) "other revenue," overwhelmingly the Australian Government R&D Tax Incentive (RDTI) refundable offset — AUD 1,937k in FY26 — plus small interest income. There is no product sales revenue in the conventional sense, no subscription revenue and no service-contract backlog. On a FY2026 basis the mix was approximately 45% profit share/royalty, 20% licensing milestone, 5% fee-for-service and 30% government grant (RDTI) and interest.

Value-chain position. Acrux sits at the upstream end of the pharmaceutical value chain: formulation science, analytical and CMC development, bioequivalence and clinical-study design, regulatory dossier preparation (ANDA, NDA/505(b)(2), TGA), device know-how (metered-dose applicators) and technology transfer. Downstream manufacturing, distribution, payer contracting and promotion are performed by partners.

Customer types. Acrux's direct customers are pharmaceutical companies: US generic marketers (TruPharma for nitroglycerin and dapsone; Padagis for Evamist and, until December 2025, the prilocaine/lidocaine cream), a European branded women's-health company (Gedeon Richter Plc for Lenzetto in 40+ countries, and from May 2026 Australia), a Gulf distributor (Servacure Trading W.L.L. for Dapsone 5% in Saudi Arabia, July 2025), and fee-for-service clients. Prospective co-development partners for Female Testosterone are, per the FY26 Chair/CEO report, undertaking due diligence in Acrux's data room; none has been named.

End-markets. Historically the US generic dermatology/topical prescription market (acne, anal-fissure pain, topical anaesthesia, onychomycosis) and the global menopause hormone therapy (MHT) market. Prospectively, female sexual dysfunction (HSDD) and broader women's health (premature menopause, post-cancer sexual dysfunction, potentially cognitive symptoms).

Independent characterisation. Acrux is best understood today as a single-asset, partnering-dependent women's-health development company with a small, declining-risk royalty "annuity" attached. Its balance sheet is thin (AUD 1.7 million cash and AUD 1.5 million equity at 30 June 2026) and its FY2026 near-breakeven result (net loss AUD 604k) was enabled by non-recurring items (a AUD 1.35 million signing milestone and AUD 829k ANDA-divestment proceeds). The strategic pivot is rational given the commoditisation of US topical generics that management itself cites, but it transforms the investment case from incremental ANDA execution into a binary bet on securing a well-funded partner for a Phase III programme in an indication where several prior testosterone-for-women efforts (P&G's Intrinsa patch in Europe, BioSante's LibiGel) have failed commercially or clinically. Acrux's genuine differentiators are its heritage IP and know-how in metered-dose transdermal sprays, a completed Phase II dataset (the 90 µL dose met its primary endpoint on satisfying sexual events), existing FDA and TGA regulatory dialogue, and a long-standing relationship with Gedeon Richter, which already markets an Acrux spray in over 40 countries.

Strategy

Stated strategy (FY26 Annual Report themes). The FY26 Annual Report frames the year as one in which Acrux "transformed its business by monetising existing assets and established a core income stream from its portfolio of topical generic products," creating the foundation to pursue "a potentially significant new blockbuster opportunity" in Female Testosterone MDTS. The strategy rests on three stated pillars: (1) a changing regulatory and clinical environment for hormone replacement therapy (management cites growing regulatory and medical recognition, and recent changes to US hormone-therapy labelling); (2) leveraging Acrux's proven technology and know-how, including completed Phase I/II studies, to accelerate a differentiated product; and (3) addressing a substantial unmet need — approximately 4.9 million US menopausal women with HSDD, roughly 10% of adult women affected, and no FDA-approved testosterone product for women. The commercial model is co-development: Acrux contributes formulation, device, technical-transfer and regulatory capabilities, while a partner contributes clinical, financial, manufacturing and commercial resources.

This represents a decisive break from the strategy that prevailed from Q4 2017 to FY2025, whose three priorities (per the FY24 Annual Report) were revenue realisation, operational effectiveness and optimal portfolio management of US generic topicals.

ESG commitments. Acrux's ESG framework comprises environmental, social and governance tenets centred on waste and energy minimisation at its leased site; no quantified emissions targets have been set.

Medium-term financial targets and guidance. Acrux provides no quantitative revenue, earnings or cash-flow guidance and no medium-term financial targets. The only forward-looking financial statements are (a) up to AUD 4.05m of further Lenzetto Australia milestones expected from FY27, contingent on TGA approval and cumulative-sales triggers, payable within two years of launch; (b) expected FY26 RDTI of AUD 1.977m (of which AUD 0.95m already advanced); and (c) expected FY27 cost savings, unquantified. The company's own market-sizing — a US and EU HSDD market potential of US$21.3 billion per year and ~120 million women globally estimated to have HSDD by 2030 — is explicitly labelled by management as derived, illustrative and not sourced from any single market report, and should not be treated as a revenue target.

Products & Services

Acrux's portfolio is organised below into (A) the development asset now driving strategy, (B) on-market approved products generating income, (C) approved-but-not-launched or divested products, (D) discontinued pipeline, (E) legacy proprietary products, and (F) services and platform technology.

A. Development asset (strategic priority)

ProductDescription and capabilitiesTarget customerStatus (latest)Pricing modelSource
Female Testosterone MDTS (testosterone metered-dose transdermal system for women)Controlled-dose testosterone delivered through the skin of the abdomen via Acrux's proprietary applicator and "patchless patch" spray technology; designed for simple, accurate, flexible dosing and reduced risk of incidental transfer; selected dose 90 µLPre- and post-menopausal women with HSDD; potential expansion to premature menopause, post-cancer sexual dysfunction, IVF/ovarian priming and cognitive decline (exploratory)Phase I and Phase II completed (Phase II: increased satisfactory sexual events across all testosterone arms vs placebo; 90 µL dose statistically significant on primary endpoint). FDA pre-IND feedback sought July 2026 for Phase III and a potential 505(b)(2) pathway; TGA meeting December 2025 indicated a literature-based submission may be acceptable subject to bridging and device work. Not registered for any indicationCompany illustrative assumption of US$300 per month treatment cost; out-licensing/co-development model; no partner terms disclosedFY26 Annual Report; ASX 28 Apr 2026; ASX 6 Aug 2026

B. On-market products generating income (US unless stated)

ProductReference brand / indicationLicensee / marketerLaunchAddressable market (IQVIA, 12 months to June 2024)Economics to AcruxSource
Nitroglycerin Ointment 0.4%Generic of AbbVie's Rectiv; pain associated with chronic anal fissureTruPharmaDecember 2024US$22.7mProfit shareFY24 and FY26 Annual Reports
Dapsone Gel 5%Generic of Aczone 5%; acne vulgarisTruPharma (US); Servacure Trading W.L.L. (Saudi Arabia, licence July 2025)April 2024 (US)US$15.8mProfit share (US); Saudi terms not disclosedFY24 and FY26 Annual Reports
Dapsone Gel 7.5%Generic of Aczone 7.5%; acne vulgarisTruPharmaMay 2025 (FDA approval August 2024)US$37.4mProfit shareFY24 and FY26 Annual Reports
Estradiol Spray (Evamist)Menopause hormone therapy — symptoms of oestrogen deficiency post-menopausePadagis (US)Originally approved 2007—Royalty/profit share (terms not disclosed)FY24 and FY26 Annual Reports
Lenzetto (estradiol transdermal spray)MHT; ex-US brand name of Acrux's estradiol sprayGedeon Richter Plc, more than 40 countries; Australia added May 2026 (pending TGA registration)Marketed for multiple years ex-US; Australian launch pendingGedeon Richter sales of approx. EUR 50m in 2025Ex-Australia royalties sold to Richter for EUR 4.1m (January 2023); Australia: up to AUD 5.4m in milestones (AUD 1.35m received June 2026)ASX 28 May 2026; FY24 Annual Report

C. Approved but not marketed, or divested

ProductIndicationStatusSource
Efinaconazole 10% Topical Solution (generic Jublia)Onychomycosis (toenail fungus)FDA-approved; launch timing governed by a Paragraph IV patent litigation settlement agreement; settlement date and entry date not publicly disclosed in reviewed filingsFY24 Annual Report
Prilocaine 2.5% and Lidocaine 2.5% CreamTopical anaesthetic (generic EMLA); addressable market US$26.8m (IQVIA, June 2024)Launched by Padagis December 2022; ANDA divested December 2025 for US$0.55m as a "low performing" productFY24 and FY26 Annual Reports
Testosterone Topical Solution (generic Axiron)Male hypogonadismANDA divested in the June quarter 2024 due to a rapidly declining, low-priced marketFY24 Annual Report

D. Discontinued or status-uncertain pipeline

ProductIndicationLast disclosed statusSource
Acyclovir 5% CreamCold soresUnder FDA review at August 2024; post-FY24 status not disclosed in the FY26 Annual Report (which lists four FDA-approved income-generating products and states the generic pipeline was ceased) — not publicly disclosedFY24 and FY26 Annual Reports
Undisclosed early-stage generic projectsTopical, otic and ophthalmic genericsFY24: 15-product portfolio, 7 in development; FY26: "ongoing development work on the Company's pipeline of topical generic products was ceased"FY24 and FY26 Annual Reports

E. Legacy proprietary products (historical)

ProductDescriptionStatusSource
Axiron (testosterone 2% solution, underarm metered-dose applicator)Male testosterone replacement; licensed worldwide to Eli Lilly (2010); FDA-approved 2010; PBS-listed March 2013Agreement terminated September 2017; withdrawn from the US marketSmartCompany (2010); LabOnline (2013); Biotech Daily (2017)
EllavieName used outside the US for the estradiol spray in some territories (circa 2010)Superseded by Lenzetto branding with Gedeon RichterMonash University (2010); GEN (2010)
Historical pipeline (Fentanyl UDTS, Oxybutynin MDTS, Nestorone contraceptive spray with the Population Council)Early transdermal programmes circa 2004–2005Not progressed; current status not publicly disclosedLabOnline (2005)

F. Services and platform technology

Acrux offers fee-for-service technical development (formulation, analytical development, CMC, bioequivalence support) "as and when resources are available," generating AUD 346k in FY26 (FY25: nil). Its core platform is the Metered Dose Transdermal System (MDTS) or "patchless patch," a fast-drying volatile/non-volatile spray system that forms a reservoir in the skin; this underpinned Evamist/Lenzetto, Axiron and now Female Testosterone. Pricing for fee-for-service work is project-based with upfront deposits recognised as unearned revenue (AUD 72k at 30 June 2026).

Financial Narrative

Basis of preparation. Figures are from audited consolidated statements in the FY24 and FY26 Annual Reports (covering FY23–FY26) and the five-year KPI tables in those reports (covering FY22). All figures in AUD thousands unless noted. EBIT and EBITDA are computed as loss before tax plus interest expense (and plus depreciation and amortisation for EBITDA); Acrux does not report these measures.

Income statement

Notes and discrepancies: (1) FY23 interest expense uses cash finance costs (AUD 201k) as no separate P&L line was presented; FY24 likewise uses cash finance costs (AUD 179k). (2) FY23 total operating expenses of AUD 11,582k in the income statement exclude COGS of AUD 558k; the table adds COGS for comparability. (3) The FY26 KPI table in the Remuneration Report shows FY26 basic EPS of –0.16 cents, whereas the audited income statement and Note 8 show –0.14 cents; the audited figure is used. (4) FY22 net loss is from the FY22 Appendix 4E (AUD 9,834k, down 22% on FY21).

Margins and growth (computed)

Revenue CAGR (computed): FY2022–FY2026 four-year CAGR of total revenue = (6,596 / 5,103)^(1/4) – 1 ≈ 6.6%. Management's FY24 report cited a five-year CAGR of 52% for client-derived revenue and 9% for total revenue (FY19–FY24), but those figures include the AUD 3,957k of profitless API pass-through in FY24.

Commentary. The five-year income statement is dominated by one-offs rather than organic growth. FY23's AUD 11.9m revenue was inflated by the AUD 6.3m Lenzetto royalty monetisation, which converted a perpetual royalty stream into a one-time cash receipt and was accompanied by a AUD 321k impairment of the estradiol intangible. FY24's AUD 8.1m included AUD 4.0m of zero-margin API pass-through, which explains the collapse in gross margin to 51%. FY25 was the trough: revenue fell 44% to AUD 4.5m, external R&D remained elevated at AUD 2.3m, and the net loss of AUD 5.9m was the largest since FY22. FY26 is the inflection, but a qualified one: revenue rose 46% and the loss narrowed 90% to AUD 0.6m, driven by (a) a full year of Nitroglycerin and Dapsone 7.5% profit share, (b) the AUD 1.35m Gedeon Richter signing milestone, (c) AUD 0.83m from the Prilocaine/Lidocaine divestment, and (d) a 55% cut in external R&D (AUD 2,308k to AUD 1,041k) and a 17% cut in employee costs (AUD 5,093k to AUD 4,234k) as the generic pipeline was shut down. Excluding the two non-recurring items (AUD 2.18m), FY26 loss before tax would have been approximately AUD 2.65m. The fall in RDTI income (AUD 3,298k to AUD 1,937k) is a direct consequence of reduced eligible R&D spend and will persist unless Phase III spending ramps up.

Balance sheet

FY2022 cash is the opening cash balance of FY2023 per the FY24 cash-flow statement; FY2022 equity and accumulated losses are the 1 July 2022 opening balances per the FY24 statement of changes in equity.

Commentary. The balance sheet has contracted from AUD 13.3m total assets (FY23) to AUD 5.8m (FY26), and equity from AUD 8.7m to AUD 1.5m despite AUD 4.3m of equity raised across FY25–FY26. Intangibles have been nil since the January 2023 estradiol impairment, so book value is essentially cash, the RDTI receivable and the lease right-of-use asset. The only borrowing is the Radium Capital RDTI advance (AUD 950k at 16% p.a.), secured against the FY26 RDTI receivable of approximately AUD 1.98m and repayable when the ATO pays (expected around the December 2026 quarter). The PDF structure prohibits medium- or long-term debt, so the company cannot lever its balance sheet even if lenders were willing. Note the Appendix 4E reports net tangible assets per share of 0.3 cents in both FY25 and FY26.

Cash flow

Commentary. FY26 delivered the first positive operating cash flow (AUD 1.02m) since FY23, the product of a near-tenfold increase in receipts from product agreements (AUD 521k to AUD 4,969k) and AUD 2.0m lower payments. The 31 July 2026 Appendix 4C described FY26 customer receipts as up 960%, with AUD 5.002m received; the audited cash-flow statement shows AUD 4.969m versus AUD 0.521m (+854%) — a discrepancy of AUD 33k in the FY26 figure and in the growth percentage, likely reflecting classification differences between the 4C and the audited statements. FY26 cash also benefited from a timing effect: the AUD 3.05m FY25 RDTI rebate was received in September 2025, while the FY26 rebate (approximately AUD 1.98m) falls into FY27. Management stated in the 4C that it had approximately nine quarters of funding, while the audited liquidity note states funding for at least 15 months from balance date "together with the initiatives outlined" — the two are not inconsistent but the 4C figure relies on the standard Appendix 4C methodology, which ignores planned Phase III commitments.

Ratios (computed from filed figures)

ROIC invested capital = equity + borrowings + lease liabilities – cash (FY26: AUD 2,280k). Net debt/EBITDA is not meaningful where EBITDA is negative (FY24, FY25; cells left blank). DSO uses receivables from contracts with customers divided by revenue from product agreements × 365; the FY25 figure is distorted by year-end timing of TruPharma receivables. The cash conversion cycle is not meaningful because Acrux holds no inventory and has no trade-payable cycle linked to sales; it is therefore not reported.

Ratio commentary. Every profitability ratio is negative over the period, and returns are essentially meaningless on a AUD 1–3m equity base. The most relevant metrics for this company are liquidity and dilution rather than return on capital: the current ratio has recovered to 1.37x, but the business remains dependent on RDTI pre-funding at 16% interest and on equity issued at sub-one-cent prices. Shares on issue have grown 83% between FY22 (285.4m) and FY26 (522.8m), and by roughly 106% to approximately 588.5m after the July 2026 Tranche 2 issue.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue stream (AUD K)

Revenue stream (AUD K)FY2022FY2023FY2024FY2025FY2026

Profit share and royalty income (AUD K)

—1,5341,1341,1902,948

API pass-through sales (AUD K)

—5583,95700

Lenzetto royalty monetisation (AUD K)

—6,337000

Licensing / milestone income (AUD K)

—0001,350

Fee for service income (AUD K)

—000346

RDTI grant revenue (AUD K)

—3,3772,8733,2981,937

Interest (AUD K)

—1221344015

Total revenue (AUD K)

5,10311,9288,0984,5286,596

Revenue by Segment and Segment Margins & Growth (%)

Segment metric (single segment, AUD K)FY2022FY2023FY2024FY2025FY2026

Segment revenue (AUD K)

5,10311,9288,0984,5286,596

Segment result = loss before tax (AUD K)

-9,582-212-5,568-5,937-469

Segment pre-tax margin (%, computed)

-187.8-1.8-68.8-131.1-7.1

Revenue YoY growth (%, computed)

—133.7-32.1-44.145.7

Contribution to total revenue (%)

100100100100100

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Total revenue (AUD K)

5,10311,9288,0984,5286,596

Revenue from product agreements (AUD K)

—8,4295,0911,1904,644

Other revenue incl. RDTI and interest (AUD K)

—3,4993,0073,3381,952

Cost of goods sold (AUD K)

—5583,95700

Gross profit (AUD K, computed)

—11,3704,1414,5286,596

Employee benefits expense (AUD K)

—4,9604,9155,0934,234

External R&D expense (AUD K)

—3,8122,4182,3081,041

Depreciation and amortisation (AUD K)

—595510467438

Impairment (AUD K)

—321000

Total operating expenses incl. COGS (AUD K)

—12,1409,70910,4647,065

Interest expense (AUD K)

—201179303282

EBIT (AUD K, computed)

—-11-5,389-5,634-187

EBITDA (AUD K, computed)

—584-4,879-5,167251

Loss before tax (AUD K)

-9,582-212-5,568-5,937-469

Income tax expense (AUD K)

—5522328135

Net loss (AUD K)

-9,834-764-5,800-5,945-604

Basic EPS (AUD cents)

-3.46-0.27-2.00-1.69-0.14

Diluted EPS (AUD cents)

-3.46-0.27-2.00-1.69-0.14

Dividends per share (AUD cents)

00000

Weighted average shares (millions)

—286.46289.50352.16422.85

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin (%)

—95.351.1100.0100.0

EBIT (operating) margin (%)

—-0.1-66.5-124.4-2.8

EBITDA margin (%)

—4.9-60.2-114.13.8

Pre-tax margin (%)

-187.8-1.8-68.8-131.1-7.1

Net margin (%)

-192.7-6.4-71.6-131.3-9.2

Revenue growth YoY (%)

—133.7-32.1-44.145.7

Balance Sheet and Share Count (millions)

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (AUD K)

—13,2858,9637,2255,835

Cash and cash equivalents (AUD K)

5,8316,2322,9458631,705

Receivables incl. RDTI (AUD K)

—3,3062,8893,7912,370

Total current assets (AUD K)

—9,8915,9814,8034,108

Total current liabilities (AUD K)

—2,3903,7224,4802,996

Short-term borrowings — RDTI advance (AUD K)

—01,4871,727950

Long-term borrowings (AUD K)

—0000

Lease liabilities total (AUD K)

—2,3532,2171,9081,568

Net debt excl. leases (AUD K, computed)

—-6,232-1,458864-755

Net debt incl. leases (AUD K, computed)

—-3,8797592,772813

Total liabilities (AUD K)

—4,5895,6876,2024,368

Total equity (AUD K)

9,0908,6963,2761,0231,467

Goodwill and intangibles (AUD K)

—0000

Working capital (AUD K, computed)

—7,5012,2593231,112

Accumulated losses (AUD K)

-113,723-114,487-120,287-126,232-126,836

Shares on issue (millions)

285.36288.18290.72407.76522.78

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Receipts from product agreements (AUD K)

—8,5345,6045214,969

Payments to suppliers and employees (AUD K)

—-11,445-12,771-8,770-6,731

RDTI rebate received (AUD K)

—3,7312,8692,9763,050

Operating cash flow (AUD K)

—703-4,303-5,4711,019

Capital expenditure (AUD K)

—11927650

Free cash flow (AUD K, computed)

—584-4,579-5,4761,019

Net equity raised (AUD K)

—003,376868

Net short-term borrowings (AUD K)

—01,487235-777

Lease principal repayments (AUD K)

—-183-195-217-269

Dividends paid (AUD K)

00000

Share buybacks (AUD K)

00000

Net change in cash (AUD K)

—401-3,287-2,082842

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2023FY2024FY2025FY2026

ROE (%, net loss / average equity)

-8.6-96.9-276.6-48.5

ROA (%, net loss / average total assets)

-5.8-52.1-73.4-9.2

ROIC (%, EBIT / invested capital net of cash)

-0.2-133.6-148.5-8.2

Current ratio (x)

4.141.611.071.37

Debt to equity excl. leases (x)

0.000.451.690.65

Debt to equity incl. leases (x)

0.271.133.551.72

Net debt incl. leases to EBITDA (x)

-6.64——3.24

Interest coverage EBIT / interest (x)

-0.05-30.11-18.59-0.66

Asset turnover (x, revenue / average assets)

0.900.730.561.01

Days sales outstanding, customer receivables (days)

17022130

Revenue by Region

Region (AUD K)FY2022FY2023FY2024FY2025FY2026

Australia (AUD K)

———3,3383,648

United States (AUD K)

———1,1902,948

Europe and other countries (AUD K)

———00

Total (AUD K)

5,10311,9288,0984,5286,596

Region growth

FY2026 vs FY2025

————

Australia

+9.3% (AUD 3,338k to AUD 3,648k): RDTI fell AUD 1,361k but was more than offset by the AUD 1,350k Richter milestone and AUD 346k fee-for-service income

————

United States

+147.7% (AUD 1,190k to AUD 2,948k): full-year Nitroglycerin and Dapsone 7.5% profit share plus AUD 829k divestment proceeds; approximately +78% excluding divestment

————

Europe and other

Nil in both years following the January 2023 sale of Lenzetto royalties; the Saudi Arabian Dapsone licence (July 2025) generated no disclosed revenue

————

Per-Share Data and Share Count (millions)

MetricFY2020FY2021FY2022FY2023FY2024FY2025FY2026

Share price at 30 June (AUD cents)

14.513.05.24.27.01.61.2

Shares on issue (millions)

168.58283.31285.36288.18290.72407.76522.78

Market capitalisation (AUD Mn)

24.4436.8314.8412.1020.356.936.27

Valuation Multiples

MultipleAcruxComment

EV/EBITDA

~29x

On computed FY26 EBITDA of AUD 0.25m; not meaningful given one-off income

EV/Sales (total revenue)

~1.1x

On FY26 revenue of AUD 6.6m (includes RDTI)

EV/Sales (product-agreement revenue)

~1.6x

On FY26 AUD 4.64m

P/B

~4.4x

On FY26 equity of AUD 1.47m

Capital Instruments

InstrumentNumberExercise priceExpiry

ACRO listed options

160,472,177

5.25c

19 Feb 2027

Placement attaching options

Up to 84,210,520

1.8c

~July 2029

Lead-manager options (Alpine Capital)

26,228,068

1.8c

~July 2029

CEO options

8,000,000

2.31c (Tranche 1; later tranches ≥ that)

December 2032

Rights held by directors and employees

16,265,181

Various (nil to 7.9c hurdle)

2030–2032

Loan-funded ESOP shares approved (CEO and NEDs)

Up to 15,750,000

Interest-free limited-recourse loan

—

Analyst Conclusions

Management guidance. Management offers no numeric guidance. Its stated FY27 priorities (FY26 Chair and CEO report) are to progress partnership discussions, finalise the proposed Phase III programme, and advance manufacturing and regulatory activities, while applying "disciplined capital management." It expects material FY27 savings from headcount reduction and overhead rationalisation, receipt of the FY26 RDTI (~AUD 1.98m, of which AUD 0.95m will repay Radium), and potential receipt of up to AUD 4.05m in Lenzetto Australia milestones contingent on TGA approval and sales. The directors' liquidity assessment is that cash plus planned initiatives fund operations for at least 15 months from 30 June 2026.

Consensus growth expectations. None available; the stock is effectively uncovered.

Bull case

  1. A partnership could re-rate the company several-fold. With an enterprise value of roughly AUD 7m, even a modest upfront payment from a co-development partner for a first-in-class FDA-approvable female testosterone product would be large relative to the market capitalisation; the company reports shortlisted parties are already in data-room due diligence (FY26 Annual Report).

  2. De-risked science and regulatory pathway. A completed Phase II with a statistically significant primary endpoint at the 90 µL dose, FDA feedback indicating a viable Phase III path (April 2026), a potential 505(b)(2) route, and a TGA literature-based pathway together lower the development burden relative to a new chemical entity.

  3. Self-funding base improving. FY26 delivered positive operating cash flow of AUD 1.02m, US profit share rose ~78% underlying, operating costs are falling, and up to AUD 4.05m of Lenzetto milestones provide non-dilutive upside — together reducing the need for deeply discounted equity.

Bear case

  1. The FY26 "turnaround" was manufactured by one-offs. Excluding the AUD 1.35m Richter signing fee and AUD 0.83m ANDA sale, FY26 pre-tax loss would have been about AUD 2.65m; RDTI is shrinking (AUD 3.30m to AUD 1.94m), and the generic income base is exposed to the very price erosion that prompted two divestments.

  2. Partnering is uncertain and the category has a poor record. No deal has been announced five months after a placement explicitly intended to support one; female testosterone has a history of regulatory and commercial failure (Intrinsa, LibiGel), and approved HSDD drugs have under-delivered commercially relative to large addressable-market claims like Acrux's US$21.3bn estimate.

  3. Dilution and governance overhangs. The share count has roughly doubled since mid-2024 to ~588m, with over 300m options and rights outstanding, financing at 16% interest, and a going-concern material uncertainty; a weak-negotiating-position partnership could transfer most of the asset's value to the partner.

Key catalysts and monitorables (next 12 months)

Expected timingCatalyst / monitorableWhy it matters
Q4 CY2026Announcement (or absence) of a Female Testosterone co-development agreement — upfront, milestones, cost-sharing, territorySingle most important value driver; determines funding of Phase III
Q4 CY2026Formalised FDA pre-IND feedback; Phase III design (size, duration, safety requirements)Defines cost and timeline; safety-data requirements are a key risk
Oct 2026 / Jan 2027 / Apr 2027Quarterly Appendix 4C cash reportsTracks burn, receipts, RDTI timing
Q2 FY2027Receipt of FY26 RDTI and repayment of Radium advanceLiquidity
Nov 2026AGM — remuneration, director re-elections, any capital-management resolutionsGovernance; shareholder sentiment
FY2027TGA registration of Lenzetto by Gedeon Richter (triggers regulatory milestone)Up to AUD 4.05m additional non-dilutive income across milestones
FY2027Execution of headcount and lease rationalisationCash-burn reduction; retention of key know-how
19 Feb 2027Expiry of 160.5m ACRO options at 5.25c (deep out of the money)Removes overhang; no funding expected from exercise
Feb 2027Half-year results (Appendix 4D), aggregator-listed for late Feb/early Mar 2027First read on underlying profitability without FY26 one-offs
OngoingUS profit-share trends for Nitroglycerin and Dapsone; any further ANDA divestmentsIncome-base durability

Analyst verdict

Acrux has completed one of the more consequential strategic pivots among ASX micro-cap life-science companies: from a sub-scale US topical generics developer, which by management's own admission was being squeezed by crowded, price-competitive markets, to a single-asset women's-health play centred on a Female Testosterone Metered Dose Transdermal System for HSDD. The logic is sound. Acrux's genuine edge has always been its metered-dose transdermal spray know-how, proven by Evamist, Axiron and a Lenzetto franchise that still sells around EUR 50 million a year for Gedeon Richter. The female testosterone programme has completed Phase II with a statistically significant primary endpoint, the regulatory environment for hormone therapy in women is more receptive than at any time since the programme began, and no FDA-approved female testosterone exists.

The financial reality, however, is fragile. FY2026's near-breakeven result rested on AUD 2.2 million of non-recurring income; cash is AUD 1.7 million, equity AUD 1.5 million, financing is short-term at 16%, and the auditors' going-concern disclosure remains. The company cannot fund Phase III and cannot borrow long-term; its strategy therefore reduces to a single question — can it sign a credible co-development partner on terms that leave meaningful economics with shareholders? Its bargaining position is weak, its share price sits below the strike of recently issued options, and the share count has doubled in two years.

On balance, Acrux should be viewed as a high-risk, binary, event-driven option on partnering success rather than an operating business to be valued on earnings. A well-structured deal with an established women's-health company could justify a valuation several times the current AUD 6–7 million capitalisation; failure to secure one within the next two to three quarters would likely force further deeply dilutive capital raising or asset monetisation. The next 12 months — partner announcement, FDA Phase III requirements and Lenzetto TGA approval — will decide which outcome prevails. Investors should size positions accordingly and treat management's US$21.3 billion market estimate as aspirational.


End of dossier. All figures AUD unless stated; FY ends 30 June. Derived metrics are computed from filed line items.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior rolesEducationFY26 total remuneration (AUD)

John Warmbrunn

CEO and Managing Director (Executive Director)

Since 1 June 2025

12 years in senior commercial roles at Ego Pharmaceuticals (grew export business to over 50% of turnover); Sandoz/Novartis (established OTC business in Australia and New Zealand); Bristol Myers Squibb (ConvaTec); CEO of Bendigo Community Telco (NSX: BCT), led IPO

BSc (Genetics), University of Melbourne; MBA, Macquarie Business School; MAICD

492,828 (salary 375,000; STI accrual 33,750; super 30,000; options 33,506; leave movements 20,572)

Joanna Johnson

CFO and Company Secretary

Company Secretary since June 2021

CFO/Company Secretary IDT Australia and Generic Health; Finance Director Asia Pacific, Hospira and Mayne Pharma; FH Faulding

CA; BEc (Adelaide); Grad Dip Business Management (UniSA)

318,411

Felicia Colagrande

Product Development and Technical Affairs Director

Director role since February 2015; joined Acrux 2001

Faulding Pharmaceuticals; Austin Hospital Clinical Pharmacology; Silliker-Microtech; Adjunct Lecturer, Monash Pharmacy

BSc (Hons), La Trobe; MBA, Australian Institute of Business

301,354

Mark Hyman

Project and Technical Development Director

Since July 2020

30+ years in quality, manufacturing, operations, product development and project management across prescription and consumer health

BSc (Chemistry and Pharmacology), Monash

298,873

Dr Jolanta Airey

Chief Medical Officer

Appointed 24 August 2026

CMO, Cynata Therapeutics (2021–2026); previously Medical Monitor on Acrux's testosterone formulation that led to Axiron's launch

MD (further details not publicly disclosed)

Not yet disclosed

Board of Directors

NameRoleAppointedIndependenceCommitteesBackgroundFY26 remuneration (AUD)

Ross Dobinson

Chairman

March 1998 (Chair since January 2006; Executive Chair July 2012 – October 2014)

Classified by the company as independent, although he is a founder and former CEO

Attends committees by invitation

Investment banking and stockbroking; founding director of Starpharma; former director of Reliance Worldwide, Hexima, TPI Enterprises/Palla Pharma, Roc Oil, Racing Victoria

129,319

Dr Geoff Brooke

Non-executive Director

June 2016

Independent

Audit and Risk; Human Capital and Nomination

Co-founder GBS Venture Partners (1996); founder of Medvest with Johnson & Johnson; Chair of Actinogen Medical and Cynata Therapeutics; director of Saluda Medical

83,577

Don Brumley

Non-executive Director

June 2021

Independent

Chair, Audit and Risk; member, Human Capital and Nomination

30 years as senior partner at Ernst & Young Oceania (Oceania IPO Leader, Biotech Markets Leader); former Chair of Bio-Gene Technology

83,577

Dr Tim Oldham

Non-executive Director

October 2013

Independent

Chair, Human Capital and Nomination; member, Audit and Risk

CEO and MD of AdAlta (ASX: 1AD); former President Asia Pacific, Hospira; Mayne Pharma; McKinsey

83,577

John Warmbrunn

CEO and Managing Director

1 June 2025

Executive

—

See above

492,828

Board & Management Changes

DateChangeContext

7 February 2025

CEO Michael Kotsanis announces retirement after more than 10 years

Chair credited him with implementing the generic strategy and six FDA approvals in four years

30 May 2025

Kotsanis ceases as CEO and KMP; remains employee to 4 July 2025 for transition; 4.5m unvested performance rights cancelled

FY26 Annual Report

1 June 2025

John Warmbrunn commences as CEO and MD

Commercially oriented hire from Ego Pharmaceuticals; mandate to expand international presence

24 August 2026

Dr Jolanta Airey appointed Chief Medical Officer

To lead Phase III design and execution for Female Testosterone

Major Shareholders

HolderOrdinary sharesACRO listed optionsUnvested/unexercised rights or options

Ross Dobinson

10,746,351571,428

2,257,130 rights

Don Brumley

8,809,0602,285,714

1,433,359 rights

Tim Oldham (incl. related entities)

5,198,307285,714

1,433,359 rights

Geoff Brooke (incl. related entities)

1,976,015285,714

4,826,333 rights

Felicia Colagrande

770,415285,714

1,015,000 rights

Mark Hyman

66,4770

1,015,000 rights

Joanna Johnson

00

1,015,000 rights

John Warmbrunn

00

8,000,000 options

Total KMP

27,566,625 (≈5.3% of 522.8m shares)

3,714,284

—

Competitive Landscape

Market Share by Competitor

CompetitorArenaRelevant products / positionComparative revenue / share

Taro Pharmaceutical (Sun Pharma)

Topical generics

Leading US topical/dermatology generics player

—

Glenmark Pharmaceuticals

Topical generics

Large US dermatology generics portfolio

—

Teva Pharmaceuticals

Topical generics / women's health

Broad generic portfolio including topicals and hormone products

—

Viatris

Topical generics

Generic topicals and hormone products

—

Zydus Lifesciences

Topical generics

Growing US topical generics including complex semi-solids

—

Padagis

Topical generics (also an Acrux partner)

Specialist US topical generics; markets Evamist

—

Encube Ethicals

Topical generics (CDMO / developer)

Indian topical semi-solid developer and manufacturer

—

Sprout Pharmaceuticals

HSDD

Addyi (flibanserin), FDA-approved oral therapy for premenopausal HSDD

—

Cosette Pharmaceuticals

HSDD

——

Lawley Pharmaceuticals

Female testosterone (Australia)

——

Off-label male testosterone gels and compounded products

Female testosterone

The de facto standard of care: Acrux notes women are frequently prescribed male products, creating dosing and transfer issues

Not quantified

Gedeon Richter (also partner)

Women's health / MHT

Lenzetto (Acrux-developed); broad women's-health portfolio — potential competitor or partner

Lenzetto sales ~EUR 50m (2025), per Acrux

Competitor Detail

MetricAcrux (FY2026)

Revenue

AUD 6.6m

Revenue growth

+45.7% (one-off assisted)

Net margin

–9.2%

EBITDA margin

+3.8% (computed)

R&D intensity (external R&D / revenue)

15.8% (understated; excludes in-house scientists)

Business model

Out-licensing / profit share

Company Snapshot

$4.3M

Revenue

23

Employees

1998

Founded

West Melbourne, Australia

Headquarters

SWOT Analysis

Strengths

  • Proven transdermal spray platform: Acrux's MDTS technology has produced two FDA-approved branded products (Evamist, 2007; Axiron, 2010) and underpins Lenzetto, which Gedeon Richter sold for approximately EUR 50m in 2025 (ASX, 28 May 2026).
  • Positive Phase II data: the completed Phase II female testosterone study showed increased satisfactory sexual events across all testosterone arms versus placebo, with the 90 µL dose statistically significant on the primary endpoint (FY26 Annual Report).
  • Regulatory dialogue in two jurisdictions: FDA feedback on Phase I/II and a viable Phase III pathway (April 2026), pre-IND feedback sought July 2026; TGA indicated a literature-based submission may be acceptable (December 2025).
  • Recurring, partner-funded income base: profit share and royalties from four on-market US products; FY26 product-agreement revenue of AUD 4.644m versus AUD 1.190m in FY25 (FY26 Note 4).
  • Lean, experienced technical team: core technical leaders have long tenure (Colagrande joined in 2001) and a track record of six FDA approvals in four years under the generic strategy (ASX, 7 February 2025).
  • Shareholder tax advantage: PDF status makes capital gains and dividends tax-exempt for shareholders, reaffirmed on 14 May 2026, which may support retail demand in future raisings.

Weaknesses

  • Thin balance sheet: cash of AUD 1.705m, equity of AUD 1.467m and net tangible assets of 0.3 cents per share at 30 June 2026 (FY26 Annual Report).
  • Persistent losses and going-concern uncertainty: accumulated losses of AUD 126.8m; the FY26 financial statements retain a material-uncertainty going-concern note dependent on milestones, a co-development deal and RDTI.
  • FY26 result flattered by one-offs: AUD 2.18m of non-recurring income (Richter signing fee AUD 1.35m; ANDA divestment AUD 0.83m) versus a net loss of AUD 0.60m.
  • Expensive, short-term funding: RDTI advances from Radium Capital at 16% per annum (AUD 0.95m outstanding at 30 June 2026); PDF rules prohibit medium- or long-term borrowing.
  • Severe dilution: shares on issue rose from 290.7m (June 2024) to ~588.5m (July 2026), with ~160.5m ACRO options, ~110.4m new 1.8c options and ~24.3m employee securities outstanding.
  • Board diversity and tenure: an all-male five-member board with a Chair of 28 years' tenure, at a company now positioning itself in women's health.

Opportunities

  • First FDA-approved female testosterone: no testosterone product is FDA-approved for women with HSDD; a first-mover approval could command significant value (FY26 Chair/CEO report).
  • Co-development partnership: multiple shortlisted parties are in data-room due diligence (FY26 Annual Report); an upfront payment could transform the balance sheet relative to a ~AUD 6–7m market capitalisation.
  • Lenzetto Australia milestones: up to AUD 4.05m in further milestones on TGA approval and sales triggers within two years of launch (ASX, 28 May 2026).
  • Australian regulatory fast track: a literature-based TGA submission could produce an earlier, smaller-market approval and revenue (FY26 Annual Report).
  • Indication expansion: premature menopause, post-cancer sexual dysfunction and other conditions identified as potential adjacent uses (FY26 Annual Report).
  • Further geographic monetisation of approved generics: the Saudi Dapsone deal (July 2025) shows a template for additional territory licences "on an opportunistic basis."

Threats

  • Partner failure risk: no co-development agreement has been announced more than five months after the May 2026 placement; without one, Phase III cannot proceed.
  • Clinical and regulatory risk: historical failures in the category (Intrinsa withdrawn in the EU; LibiGel Phase III failure) and FDA safety caution on testosterone in women.
  • Generic price erosion: Acrux itself states US topical generic markets have become "increasingly crowded and price competitive," prompting two ANDA divestments since mid-2024.
  • Declining RDTI: RDTI income fell from AUD 3.298m (FY25) to AUD 1.937m (FY26) as generic R&D ceased, reducing a key non-dilutive funding source.
  • Key-person and capacity risk: headcount down to ~23 with further cuts planned in FY27, concentrating know-how in a handful of individuals.
  • Equity-market access: the May 2026 placement was priced at 0.95c, a 16.8% discount to VWAP; the share price has subsequently traded around 0.9–1.1c, below the 1.8c strike of new options, limiting option-exercise funding.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
May 2025Dapsone 7.5% Gel launched in the US by TruPharmaThird US launch in 13 months; underpinned FY26 profit-share growth
30 May 2025Michael Kotsanis ceases as CEO and KMPEnd of the generic-strategy era
1 June 2025John Warmbrunn commences as CEO and Managing DirectorLeadership transition to a commercially focused CEO
4 July 2025Kotsanis employment ends; 4.5m unvested rights cancelledRemoves legacy incentive overhang
July 2025Licence with Servacure Trading W.L.L. for Dapsone 5% Gel in Saudi ArabiaFirst Middle East deal for an Acrux generic
August 2025FY2025 results: revenue AUD 4.528m, net loss AUD 5.945mTrough year; going-concern material-uncertainty language retained
September 2025AUD 3.050m FY25 RDTI rebate received from the ATOMajor liquidity injection
22 September 2025All 26 staff each granted 100,000 service-only rightsRetention tool; replaces performance-hurdle rights that repeatedly lapsed
21 November 2025Annual General Meeting approves CEO options and NED rightsGovernance
3 December 202513.1m rights issued to NEDs and 8.0m options issued to the CEOEquity remuneration
December 2025Meeting with the TGA on Female Testosterone; TGA indicates a literature-based submission may be acceptableDefines a potentially faster Australian pathway
December 2025Prilocaine/Lidocaine Cream ANDA divested for US$0.55m; generic pipeline development ceasedPortfolio pruning; signals strategic pivot
January 2026Radium Capital advance of AUD 0.95m against FY26 RDTI (spend to 31 January 2026)Bridge funding at 16% p.a.
February 2026Interim reporting
26 February 2026Notification of cessation of securitiesLapse of rights/options
28 April 2026Strategic update: focus on Female Testosterone for low libido (HSDD) and co-developmentFormal strategic pivot
11 May 2026AUD 1.6m placement at 0.95c (13.6% discount to last price, 16.8% to 5-day VWAP), scaled back from AUD 2.6m bids; 1-for-2 options at 1.8cFunding for Female Testosterone and partnering
14 May 2026Announcement that PDF status keeps shareholders' capital gains and dividends tax-exempt despite 2026/27 Budget CGT changesInvestor-relations positioning
18 May 2026Tranche 1 placement shares issued (102.65m shares, AUD 0.975m)Capital raised
28 May 2026Lenzetto licence amended with Gedeon Richter to add Australia; up to AUD 5.4m in milestones; Richter's global Lenzetto sales ~EUR 50m in 2025Non-dilutive funding; addresses Australian MHT shortage; shares rose ~20%
June 2026AUD 1.35m Lenzetto Australia signing milestone received; tax-exempt shares issued to 19 employeesFirst licensing milestone under new strategy
15 June 2026Notice of EGM issuedGovernance
July 2026FDA feedback sought following pre-IND engagement on Phase III and 505(b)(2) pathwayKey regulatory step
21 July 2026EGM approves Tranche 2, attaching options (84.2m) and lead-manager options (26.2m), new ESOP and loan-funded director/CEO sharesCapital and remuneration
24 July 2026Appendix 3Y lodged for Chair Ross DobinsonDirector interest change
29 July 2026Tranche 2 placement shares issued (65.77m shares); cleansing noticeCapital raised
31 July 2026June 2026 Quarterly Activities Report and Appendix 4C: FY26 customer receipts AUD 5.002m (+960% per 4C), quarter-end cash AUD 1.705m, ~9 quarters of fundingLiquidity update
6 August 2026Investor presentation at the Bioshares Biotech Summit on Female Testosterone for HSDDInvestor outreach; shares fell ~18% on the day
24 August 2026Dr Jolanta Airey appointed Chief Medical OfficerPhase III readiness
25–26 August 2026FY2026 results: revenue AUD 6.596m (+46%), net loss AUD 0.604m (–90%), positive operating cash flow AUD 1.019m; going-concern material uncertainty retained; unmodified audit opinionInflection toward breakeven on one-offs
22 September 2026Scheduled vesting of service-only employee rights granted September 2025Minor dilution

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Total revenue rose from AUD 5.1 Mn in FY2022 to AUD 6.6 Mn in FY2026.
Acrux Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Total revenue5.111.98.14.56.6
Revenue from product agreements—8.45.11.24.6
Other revenue incl. RDTI and interest—3.533.32
Cost of goods sold—0.6400
Gross profit—11.44.14.56.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.